Brazil is a country with a growing middle-class population, a stabilizing economy, increasing urban population, and a supportive government. The country is showing a major shift in the private healthcare sector, which is a supporting factor for the IVD market.

The Brazilian healthcare funding is supported by the Ministry of Health, which runs the government hospitals in the country. The rising interests of the Brazilian researchers in molecular testing technologies, prenatal screening, and point of care (POC) glucose testing are the primary factors augmenting the growth of the market studied.

According to the National Institute of Health, the prevalence of diabetes in Brazil was around 6.3% to 13.5% in 2016. This rising prevalence of diabetes in the country is propelling the growth of the in vitro diagnostics in Brazil. Therefore, factors, such as the rising interest of the Brazilian researchers in advanced diagnostics and high prevalence of chronic diseases, are contributing to the growth of the IVD market in the country.

Key Market Trends

Molecular Diagnostics Segment Spearheaded the Market Studied

  • Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. On the basis of technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetic, and molecular imaging.
  • Factors, such as large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment.
  • Molecular diagnostics and pharmacogenomics can be used to reduce the adverse effects and toxicity of pharmaceutical interventions and facilitate cost-effective therapy by avoiding unnecessary expensive drugs, optimizing doses and timing, and eliminating ineffective drugs. The field is rapidly evolving and remains attractive to academia and the industry.
  • The use of molecular diagnostic techniques in the development and subsequent administration of personalized medicine are likely to boost the market growth.



Competitive Landscape

Danaher Corporation, Roche Diagnostics, Becton, Dickinson and Company, bioM?rieux, and Bio-Rad Laboratories Inc. are some of the major players in the market studied. The major companies are focusing on increasing technological advancements, in order to address customer needs, like fully automated systems, which reduces manual processes and consumables and also provides fast and accurate results.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support